Stock listing

gettex:7R8 Replimune Group, Inc. Aktie

German listing (gettex) of Replimune Group, Inc. · home listing NASDAQ:REPL

Follow Replimune Group, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:REPL

$10.86 USD -0.89 (-7.6%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:REPL

Replimune Group, Inc. logo
Ticker
gettex:7R8
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • Replimune Group (NASDAQ:REPL) Q4 2025 Earnings Call

    Thu, May 22, 2025 · 8:00 AM ET

    Watch Transcript

Latest news

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

Oct 1, 2026

Replimune to Present at the Cantor Global Healthcare Conference 2026

Sep 3, 2026

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

Aug 14, 2026

Replimune Announces Pricing of $150 Million Underwritten Offering

Aug 10, 2026

Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen

Aug 6, 2026

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

Jul 30, 2026

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

Jun 29, 2026

Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

Jun 26, 2026

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 31, 2026

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026

All Replimune Group, Inc. news

Financings

  • Public offering of common stock

    Aug 14, 2026

    Closed: US$150M raised · US$12.06 a share · Leerink Partners +2

    Dealers: Leerink Partners (co-lead), J.P. Morgan (co-lead), Cantor (co-lead)

    Use of proceeds: Support the commercial launch of TUDRIQEV and the ongoing IGNYTE-3 confirmatory trial

    Announced Aug 10, 2026 · Closed Aug 14, 2026

Read by 6ix AI from the company's releases

Decks

Replimune Group, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 137 in all · newest Oct 1, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest May 22, 2025
Decks
8 decks · latest Aug 6, 2026

Where Replimune Group, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:REPL · Home listingNASDAQUnited StatesUSD
gettex:7R8 · This pagegettexGermanyEUR
LS Exchange:A2JQN1LS ExchangeGermanyEUR
BOATS:REPLBOATSUnited StatesUSD
Lang & Schwarz:A2JQN1Lang & SchwarzGermanyEUR
Stuttgart:7R8StuttgartGermanyEUR
Tradegate:7R8TradegateGermanyEUR
Frankfurt:7R8FrankfurtGermanyEUR
Hamburg:7R8HamburgGermanyEUR
Munich:7R8MunichGermanyEUR
Dusseldorf:7R8DusseldorfGermanyEUR

Log in to ask 6ix AI your own questions about Replimune Group, Inc.